Form 4: SeaStar Medical Director Awarded 3,000 RSUs

SeaStar Medical Holding Corp. Director John Neuman received an award of 3,000 Restricted Stock Units, vesting fully on February 6, 2027.

Summary

• John Neuman, a Director of SeaStar Medical Holding Corp. (ICU), was awarded 3,000 Restricted Stock Units (RSUs).
• The transaction occurred on February 6, 2026, with the RSUs acquired at a price of $0.
• These RSUs will vest in full on February 6, 2027.
• Following this transaction, John Neuman beneficially owns 12,200 shares of common stock directly.
• The filing also includes a Power of Attorney granted by John Neuman to Eric Schlorff, CEO, for executing SEC Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard director compensation and alignment of interests, without indicating any significant operational or financial shifts.

Positives

• The RSU award aligns the director's interests with long-term shareholder value.
• It serves as a retention incentive for key management personnel.

Future Outlook

The RSU award to Director John Neuman is structured to vest on February 6, 2027, indicating a future incentive for continued service and alignment with company performance.

Industry Context

StockSavvy.ai notes that equity awards like Restricted Stock Units are a common form of executive and director compensation across the biotechnology and medical device industries. They are designed to incentivize long-term commitment and align the interests of directors with those of shareholders, particularly in growth-oriented companies like SeaStar Medical.

Comparison to Industry Standards

• The use of RSUs for director compensation is a standard practice in the U.S. public company landscape, comparable to practices at companies like Medtronic (MDT) or Boston Scientific (BSX) for non-employee directors, though the specific award size would depend on company stage and market capitalization.
• The vesting schedule, a single full vest after one year, is a common structure for director equity awards, aiming to retain talent for at least the upcoming year.

Corporate Governance

Related Party Transactions

• The RSU award to Director John Neuman represents compensation from the company, which is a common related-party transaction in the context of executive and director remuneration.

Stakeholder Impact

• Shareholders: The RSU award aligns the director's interests with long-term shareholder value, potentially leading to better governance and strategic decisions. It also represents a minor dilution upon vesting.
• Management: The CEO, Eric Schlorff, is granted power of attorney, streamlining compliance for the director.

Next Steps

• The 3,000 RSUs awarded to John Neuman are scheduled to vest in full on February 6, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity award to a director, which is a standard compensation practice and does not provide new information that would significantly alter the investment thesis for SeaStar Medical Holding Corp. It reinforces director alignment but does not indicate material operational or financial changes warranting a change in investment stance.

Keywords

SeaStar Medical Holding Corp, ICU, John Neuman, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Form 4, Equity Award